Key Highlights
- Vivos Therapeutics develops and markets non-surgical, non-invasive treatments for sleep-disordered breathing, centred on its proprietary CARE oral appliance technology and a network of trained dental and medical providers.
- Verified results show real commercial momentum.
- Upcoming catalysts include the planned Q1 2027 launch of the Florida center, progress on the Greenway Health AI rollout, and further quarterly results that could confirm whether the Revenue trajectory holds.
- The dominant risks are financial.
A sleep-medicine company posting double-digit revenue growth would normally command a healthier share price than Vivos Therapeutics, Inc (NASDAQ:VVOS) currently does. Trading below $0.20 in September 2026, the Colorado-based maker of oral appliances for obstructive sleep apnea and related airway disorders is delivering its strongest top-line numbers yet, even as heavy losses, a slim cash balance and steady dilution keep the stock languishing in penny-stock territory.
The gap between commercial traction and market valuation is the central tension for VVOS shareholders.
Company and Latest Development
Vivos Therapeutics develops and markets non-surgical, non-invasive treatments for sleep-disordered breathing, centred on its proprietary CARE oral appliance technology and a network of trained dental and medical providers. The company has been leaning into clinical expansion and partnerships. Recent moves include opening a new 8,100-square-foot Facility in Henderson, Nevada, in late August 2026 and signing a collaboration with South Palm Cardiovascular Associates to launch a Florida Sleep and Airway Medicine Center targeted for early 2027. Vivos also broadened a Partnership with Greenway Health to deploy an AI platform across its clinical operations and secured a new Patent extending protection for its CARE appliance line.
What Is Driving Attention Around VVOS?
The snapshot headline points to a daily pullback, but no single verified public catalyst explains that specific move; sub-dollar stocks routinely swing on thin volume. The more substantive story is financial restructuring. On 8 September 2026, Vivos exchanged $2.86 million of Debt principal for 11.4 million common shares with Streeterville Capital, cutting that note balance to roughly $3.7 million from an original $8.2 million. The swap eases the debt load but adds shares, illustrating exactly the dilution pressure weighing on the stock.
Key Numbers and Company Position
Verified results show real commercial momentum. Second-quarter 2026 revenue reached $5.2 million, up 35% year-over-year, while first-half revenue climbed 51% to $10.3 million. Gross margins improved to the 57-58% range. Yet the company still posted a Q2 net loss of about $5.5 million and reported cash of just $1.8 million as of 30 June 2026. Management also cited a 212% surge in new patient referrals over a six-week stretch, and a study of its Vida appliance reported improvement in insomnia severity among participants. With a Market Capitalisation of only a few million dollars, VVOS trades as a micro-cap despite its growth.
What Could Come Next?
Upcoming catalysts include the planned Q1 2027 launch of the Florida center, progress on the Greenway Health AI rollout, and further quarterly results that could confirm whether the revenue trajectory holds. Any additional financing or debt-for-equity actions would be closely watched given the low cash balance. Continued growth in provider adoption and patient referrals may influence sentiment, as could any move to address the stock's sub-dollar price and Nasdaq listing standards.
Risks to Watch
The dominant risks are financial. With cash near $1.8 million against ongoing losses, Vivos faces clear funding pressure and a real prospect of further dilution, as the September debt swap demonstrated. A share price under $0.20 raises Nasdaq minimum-bid concerns. Competition in sleep apnea therapy, from CPAP devices to rival oral appliances and drug-based approaches, is intense. Execution risk on new facilities and partnerships remains, and thin Liquidity amplifies volatility.
Vivos Therapeutics presents a genuine paradox: accelerating revenue and expanding clinical reach set against a penny-stock valuation and a fragile balance sheet. The recent debt reduction and strong first-half sales are tangible positives, but the cash position and dilution keep risk elevated. Investors may want to monitor upcoming quarterly results, the Florida center launch, cash and financing developments, and any steps to shore up the Nasdaq listing.






Please wait processing your request...